Chapter Summaries

Director Sun reviewed the Sanqing drug’s successful treatment of severe poisoning cases and recalled patients who might have been saved by it. When a group of sailors arrived with signs of radiation sickness, test results revealed radioactive dried fish had caused chronic internal radiation, and Director Sun rushed to report the discovery.

• Director Sun read a report documenting more than a hundred poisoning and radiation-sickness patients who recovered after taking Three Purities’ Sanqing drug.
• Director Sun recalled a nuclear radiation victim and a boy poisoned by Paraquat, and considered how the new antioxidant medicine might have saved them.
• Eight sailors arrived with nausea, bleeding, low blood counts, and blistered red skin, so Director Sun ordered bone marrow tests while doctors investigated possible food poisoning.
• Ten more people with the same symptoms were admitted the next morning, prompting Director Sun to order a thorough examination of all the patients.
• Director Sun learned that dried fish from the sailors’ dormitory contained excessive radioactive substances and that their poor bone marrow production confirmed chronic internal radiation sickness.
• Director Sun told the staff to treat the patients and ran to report the urgent discovery to his superiors.

Investigators traced radioactive contamination in deep-sea fish and widespread radiation sickness to polluted waters in the North Pacific, triggering public panic and an international investigation. The investigation team exposed the responsible country, which denied wrongdoing and insisted its actions were reasonable.

• Medical workers found radioactive residue in dried fish at Deep Sea Ocean Fishery headquarters, and investigators learned that contaminated catches might already have reached the market.
• Li Hua's emergency team concluded that fishing vessels' catches were contaminated, while news reports about suspected nuclear pollution sparked panic, medical checkups, and shortages of anti-radiation medicine and iodized salt.
• Saul and Chris discussed secretly dumping nuclear waste and planned to blame Bear Country, but Saul received a call summoning him for questioning.
• A warship's investigators detected increasing radioactive contamination as they traveled north toward Radiation Island, helping identify the polluted waters and the culprit.
• Li Hua reported the findings, and the investigation team publicly revealed the evidence; the responsible country denied wrongdoing and claimed its actions were reasonable.

Global outrage over Sakura Country’s nuclear wastewater discharge intensified as the first fishermen treated with Three Purities’ Xifuning recovered and were discharged. The drug’s apparent effectiveness left the public eager to learn whether Three Purities had developed it and when it would become available.

• A global news bulletin identified Fukushima Nuclear Power Plant as the source of widespread Pacific contamination, prompting protests, seafood bans, and condemnation of Sakura Country.
• Sakura Country apologized but refused to stop the discharge, while Eagle Country opposed punishment at the Global Alliance conference and drew suspicion of a secret agreement.
• Director Sun told Li Hua that the fishermen were improving with Xifuning and were expected to recover fully within one or two weeks.
• After four weeks of treatment, the first thirty-two fishermen with chronic radiation sickness were discharged from 307 Hospital in good health.
• Netizens connected Xifuning to Three Purities and flooded the company’s customer service hotline with questions about the drug.

Sanqing Group confirmed that its new drug, Xifuning, was in Phase III trials and expected to launch next year, while public anxiety over radiation grew after reports exposed nuclear wastewater discharges in Eagle Country. The chapter left Xifuning as a widely anticipated source of hope amid fears of radioactive contamination spreading worldwide.

• Sanqing Group announced that its unnamed antioxidant-enzyme drug, which people called Xifuning, was in Phase III trials and could launch next year.
• Netizens debated the drug's delayed release and worried that seafood and radiation exposure had already harmed their health.
• Eagle Country media reported that a nuclear power plant beside the Mississippi River had secretly discharged more than two million liters of nuclear wastewater over several months.
• Eagle Country's government described the leak as low risk, but local residents and international netizens criticized the secrecy and feared radiation damage.
• Chinese netizens reacted to the foreign contamination reports with alarm and saw Xifuning as protection against radiation.
• Overseas media publicized Three Purities' drug, and the public embraced Xifuning as a lifeline amid the alarming news.

As nuclear contamination drove Jim and Jamie to search desperately for safe water and medicine, they learned of China’s radiation treatment and decided to protest at city hall. In Sakura Country, leukemia-stricken fisherman Nishimura Yasuo joined a plan against the officials responsible for the ocean discharge and attacked a suited man outside the official residence.

• Jim and Jamie found pharmacies stripped of supplies, and a pharmacist demanded 500 dollars per pack of potassium iodide tablets.
• Jamie told Jim that Three Purities’ Xifuning had reportedly treated radiation sickness in China, prompting Jim to turn the car toward city hall to protest.
• Nishimura Yasuo, a Fukushima fisherman, learned that his leukemia had been caused by radioactive exposure and agreed to help the Fishermen’s Association with its plan.
• Nishimura approached a suited man arriving at the official residence, pulled a long tube from his coat, and lunged as it fired three times.

After Sakura Country’s nuclear wastewater crisis prompted global outrage, Wei Kang used Xifuning’s overseas trials as leverage to push for action against the pollution. With the crisis addressed and overseas trials approved, he began planning a major anti-aging study.

• Sakura Country’s prime minister was stabbed by Nishimura, and authorities continued defending the wastewater discharge while pointing to Xifuning as a treatment for radiation sickness.
• Wei Kang told Andre that Sanqing would prioritize domestic demand and that overseas trials depended on countries taking action against the pollution.
• Sakura Country agreed to shut down the Fukushima Nuclear Power Plant and upgrade its wastewater treatment system after international pressure and negotiations.
• Wang Guiqing told Wei Kang that overseas clinical trials were approved, with participating countries covering costs and providing expedited approval.
• Wei Kang notified Andre of the approval and decided to pursue a five-year anti-aging clinical study with Pangu Research Institute.

Jim joined Xifuning’s long-term anti-aging clinical trial after seeing the nuclear plant apparently operating again, while Nishimura Yasuo learned he would receive medical parole and treatment. The chapter ended with Nishimura grieving that he could no longer fish and that his family’s three-generation livelihood was gone.

• Jim and Jamie celebrated being accepted into Xifuning’s radiation-sickness trial, then spotted white smoke rising from the nuclear plant and feared it had secretly restarted.
• At St. Mary’s Hospital, a doctor offered Jim a place in a five-year Xifuning trial studying whether antioxidants could delay aging, and Jim signed up immediately.
• Jim decided the trial could help protect him from continuing pollution, though Jamie and Jim’s family members were too young to qualify.
• Nishimura Yasuo’s lawyer told him his medical parole had been approved and that he could receive treatment for leukemia and radiation sickness.
• After the lawyer left, Nishimura broke down in tears, mourning that he could never fish again and that his family’s livelihood had ended.

Ding Mian explained the challenges of tissue engineering and proposed developing an artificial bladder using techniques and biomaterials from Xue Shen’s artificial blood vessel project. Xue Shen agreed to join the project.

• Xue Shen finished the successful pig animal experiments for the artificial blood vessel and prepared to apply for human clinical trials.
• Ding Mian visited Xue Shen and described how tissue engineering relied on scaffolds, cells, and blood vessel growth to create artificial organs.
• Ding Mian explained that large artificial organs remained difficult to build because researchers lacked enough cells and could not provide them with adequate blood supply.
• Ding Mian proposed an artificial bladder made from cultured patient cells on a biodegradable scaffold, using elastin from the artificial blood vessel research.
• Xue Shen agreed to work with Ding Mian on the artificial bladder project.

Wei Kang approved the Artificial Bladder Project and discussed the diagnostic AI project with Wenren Long, who then sought help with an artificial-organ enlargement surgery for a friend. Ding Mian explained his past research and said he had experience with the procedure, leaving Wenren Long hopeful that the project could proceed.

• Wei Kang approved the Artificial Bladder Project and reviewed Wenren Long's progress on the diagnostic AI project with Xiang Gaofei.
• Wenren Long asked Wei Kang whether artificial organs could be used for enlargement surgery, claiming that a childhood friend wanted it.
• Wei Kang said the procedure might be possible and left its feasibility to Ding Mian.
• Wenren Long found Ding Mian and Xue Shen at the cafeteria and tried to recruit them for the enlargement surgery project.
• Ding Mian described his experiments transplanting bioengineered organs into rabbits and recalled that his senior brother had eventually made a human organ in a laboratory.

Ding Mian recounted his failed research into lab-grown human organs and discussed easier enlargement procedures with Wenren Long. Xue Shen learned that the artificial blood vessel clinical trial had been approved, and a television crew then covered the first clinical use of Sanqing Group’s vessels in a major aortic replacement operation.

• Ding Mian described how his team built a miniature human organ from donor scaffolds and patient cells, but the patient's immune system destroyed it and its erectile function could not be verified.
• Ding Mian said he had rejected other research teams' invitations in Eagle Country to avoid being kept there, prompting Xue Shen and Wenren Long to exchange knowing looks.
• Ding Mian outlined existing enlargement procedures and warned Wenren Long that his artificial-organ research still carried considerable risks.
• Xue Shen received news that the artificial blood vessel clinical trial had been approved through the Innovative Achievement Fast Track.
• A Kun City Television Station reporter entered Kun City First People's Hospital's cardiac surgery department and introduced Director Li's operation to replace a patient's aorta and major arteries with Sanqing Group artificial blood vessels.

A female reporter observed a fifteen-hour total aortic replacement surgery at Kun City First People's Hospital and interviewed Cleveland Clinic doctors about the procedure and Sanqing Group’s Artificial Blood Vessels. The operation succeeded, though the patient still faced a difficult recovery in the ICU.

• The reporter learned from Doctor George that Cleveland Clinic doctors were training at the hospital and that the surgical team had chosen to replace the patient’s entire aorta and major branches in one operation.
• Doctor George described the patient’s dangerously thin, torn aortic wall and the complex procedure, including multiple incisions, extracorporeal circulation, and Artificial Blood Vessel grafts.
• The surgical team completed the vascular reconstruction, and after fifteen hours the patient was transferred to the ICU while the reporter learned that postoperative recovery remained uncertain.
• Two exhausted doctors collapsed after leaving the operating room, and Doctor George rushed to support them as colleagues carried them away.
• The reporter showed viewers the Artificial Blood Vessels made by Sanqing Group, explained their expected lifelong use, and ended the program with a warning about Aortic Dissection symptoms and risk factors.

Yun Feng explained why his department used Three Purities’ artificial blood vessels amid a shortage of imported grafts. In Yangcheng, a fish bone pierced a patient’s aorta, and surgeons struggled to find a graft for emergency surgery until a resident suggested a domestic option.

• Yun Feng reported that the patient who received a one-meter aortic replacement was recovering well and explained that Three Purities’ grafts were free, effective, and less vulnerable to supply shortages than imported products.
• Doctor Cao discovered that a fish bone had pierced a patient’s esophagus and thoracic aorta, and specialists decided that emergency surgery was necessary after the patient began vomiting blood and went into hemorrhagic shock.
• The directors of Cardiothoracic Surgery and Gastroenterology learned that Yangcheng hospitals had no artificial blood vessels in stock and that Beijing Anzhen Hospital had only five grafts, all allocated.
• The director of Cardiothoracic Surgery considered contacting more hospitals after Professor Zhang could offer no graft, but a resident suggested trying a domestic artificial blood vessel.

Sanqing’s biomaterial artificial blood vessel entered clinical use and helped save a patient who needed thoracic aortic replacement, while reports of its success spread across China. Terumo and Maquet executives assessed the new competition, with Maquet deciding to focus on restoring production capacity as Sanqing expanded into the market.

• Director Wang learned that Sanqing’s artificial blood vessel had succeeded in a total aortic replacement and secured a clinical trial vessel for his patient.
• The surgical team replaced the patient’s thoracic aorta, removed the fishbone that had caused the damage, and later transferred the recovering patient to the regular ward.
• Sanqing’s artificial blood vessel drew widespread public and medical attention after reports highlighted its biocompatibility and successful clinical use.
• Terumo CEO Jiro Sato blamed Sanqing’s product for threatening Terumo’s Chinese sales and considered withdrawing from China.
• Maquet CEO Fischer and technical director Hank judged Sanqing’s product a limited threat for now and chose to prioritize restarting their factory and restoring production.

Fischer dismissed the threat of Three Purities’ artificial blood vessels while focusing on restoring production. At Kun City First People's Hospital, doctors treated Old Man Liu’s repeatedly blocked dialysis fistula with a five-millimeter Three Purities vessel, restoring blood flow through a successful transplant.

• Fischer concluded that Maquet had little to fear from Three Purities unless it had solved the challenge of small-diameter artificial blood vessels, then turned his attention to the new factory’s production capacity.
• Old Man Liu arrived at Kun City First People's Hospital after his fourth AV Fistula blockage, and doctors found a thrombus that did not respond to Urokinase treatment.
• The doctors ruled that another autologous fistula was unlikely to last and chose to replace Old Man Liu’s blocked vessel with a Three Purities artificial blood vessel.
• Three Purities’ representative supplied a five-millimeter vessel designed for long-term needle punctures and self-healing, and the surgeons transplanted it into Old Man Liu’s arm.
• The surgeons restored blood flow through the new vessel, and the team confirmed a vascular thrill and blood flow on ultrasound.

Old Man Liu received dialysis through a small-diameter Artificial Blood Vessel implanted to create an AV Fistula, and his case convinced doctors that Three Purities's vessel could improve treatment for patients with Kidney Failure. At Huaxi Hospital, the Nephrology and Urology departments reviewed the case and agreed to pursue clinical trial cooperation with Three Purities.

• Nurse Li dialyzed Old Man Liu through his newly implanted Artificial Blood Vessel, and he praised its comfort and durability.
• Director Gao promoted Old Man Liu's successful AV Fistula case to colleagues and urged the Urology Department to use the vessel for more dialysis patients.
• Dr. Tang saw the case spreading through Moments and joined the Huaxi Hospital director and department staff to review the patient's records and discuss the surgery.
• Nephrology and Urology doctors agreed that the small-diameter Artificial Blood Vessel could replace damaged vessels and offer dialysis patients a practical alternative to external tubes and catheters.
• The two department directors contacted Three Purities's representative and settled on a clinical trial cooperation arrangement, leaving Dr. Tang relieved that dialysis could become easier for patients.

Sanqing introduced its Small-bore Artificial Blood Vessels at Huaxi Hospital, where doctors began preparing a Phase III clinical trial and Dr. Tang told dialysis patients they could apply for free treatment. The product’s success excited domestic manufacturers and left foreign rivals Terumo and Maquet facing the loss of their market, while Wei Kang imagined Sanqing becoming the industry leader.

• Sanqing’s research team presented large-, medium-, and small-bore Artificial Blood Vessels to Huaxi Hospital doctors and described their clinical data, available sizes, and potential uses.
• Huaxi Hospital department heads praised the samples and prepared to use them for patients needing arterial replacements, dialysis access, and other procedures.
• Dr. Tang visited the Dialysis Room, announced that Sanqing’s Small-bore Artificial Blood Vessels were entering a Phase III trial, and urged eligible patients to apply for free treatment.
• Other major hospitals began early Phase III trials, and news of Sanqing’s small-bore breakthrough spread through the medical-device industry.
• Domestic manufacturers welcomed the new development, while Terumo and Maquet were left unable to compete with Sanqing’s products.
• Wei Kang imagined Sanqing taking more than half the market in multiple fields and becoming the leading Artificial Blood Vessel company.

Wei Kang reviewed Three Purities' drug and medical-device projects before Xiang Gaofei demonstrated Sky Eye 1.0, an AI system that diagnosed common illnesses and managed patient care. Wei Kang approved further testing but planned to use Anmei to upgrade the rudimentary system.

• Wei Kang reviewed the Artificial Blood Vessel and drug projects, then examined the Artificial Heart's progress and identified its monitoring system as the main bottleneck.
• Xiang Gaofei and his team tested the diagnostic AI on patient records, finding that it could accurately assess many common illnesses, interpret scans, and guide patients to care.
• After three days of testing more than three hundred patients, Xiang Gaofei named the successful test version Sky Eye 1.0 and requested internal testing.
• Xiang Gaofei demonstrated Sky Eye 1.0 to Wei Kang, who praised its results but said he wanted to try it himself before internal testing.
• After Xiang Gaofei left, Wei Kang judged the system too primitive and called for Anmei to help upgrade it.

Wei Kang had Anmei optimize Xiang Gaofei’s diagnostic AI into a humanlike virtual doctor named Xiao Mei, then decided Sanqing would launch a public test immediately after its press conference. Sanqing announced Tianyan Diagnostic AI, drawing widespread interest as its press conference began.

• Wei Kang had Anmei create a realistic, friendly female doctor avatar and named her Xiao Mei.
• Xiao Mei used Wei Kang’s wristband data to report that he was healthy, impressing Xiang Gaofei with her lifelike appearance and manner.
• Xiang Gaofei proposed closed beta testing, but Wei Kang ordered Sanqing to open public testing after the press conference.
• Sanqing announced the development of Tianyan Diagnostic AI, prompting online discussion about its potential to help patients and provide family medical care.
• Sanqing’s diagnostic AI press conference began as the public eagerly awaited the demonstration.

Wei Kang introduced Three Purities’ medical diagnostic AI, Sky Eye 1.0, at a launch event and invited attendees to test it. Xiao Mei’s precise analysis of a patient’s scans and test results left Doctor Xue and the audience astonished.

• Wei Kang presented Sky Eye 1.0 and described how it could assist patients and doctors.
• Wei Kang introduced Xiao Mei, a realistic virtual doctor who interacted with him through speech and camera input.
• Wei Kang invited Doctor Xue to demonstrate the AI, and Xue uploaded a patient’s CT images, blood tests, and leg photos.
• Xiao Mei identified a femoral bone defect, diagnosed a fracture complicated by infection, and recommended treatment that matched Xue’s own assessment.
• The audience erupted into whispers and commotion after seeing Xiao Mei’s diagnostic performance.

At Sanqing’s launch event, Wei Kang demonstrated Xiao Mei’s reporting assistance and her ability to handle difficult patients with patience and deference. Director Xu praised her service, leaving Wei Kang to present her as the ideal medical assistant for managing patients’ anger.

• Doctor Xue praised Xiao Mei’s diagnostic abilities but left the stage after Wei Kang said each guest could try her only once.
• Reporter Cao asked Xiao Mei to write a medical-AI news report, and she quickly produced an illustrated article that he wanted to use until Wei Kang explained Sanqing owned its copyright.
• Director Xu tested Xiao Mei by demanding diagnoses, prescriptions, a CT order, and sleeping pills, but she followed hospital rules and apologized sincerely when he threatened to complain.
• Director Xu applauded Xiao Mei’s handling of his provocations and said hospitals needed someone who could remain composed with troublesome patients.
• Wei Kang explained that Xiao Mei could absorb patients’ anger on doctors’ behalf and called her the perfect tool for the job.